Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis

Chest

Volumn 149, Issue 6, 2016, Pages 1384-1392

  Huang, Qingyuan ^a   Li, Jinhui ^b   Sun, Yihua ^c   Wang, Rui ^a   Cheng, Xinghua ^a   Chen, Haiquan ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

adjuvant treatment; epidermal growth factor receptor tyrosine kinase inhibitors; non small cell lung cancer; operable; survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ACNE; ADVERSE OUTCOME; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DYSPNEA; FATIGUE; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SURVIVAL RATE; SURVIVAL TIME; VOMITING; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84973520024     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2015.12.017     Document Type: Article

References (29)

1. R. Rami-Porta, V. Bolejack, J. Crowley, and et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer J Thorac Oncol 10 7 2015 990 1003
2. R. Arriagada, A. Auperin, S. Burdett, and et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data Lancet 375 9722 2010 1267 1277
3. J.P. Pignon, H. Tribodet, G.V. Scagliotti, and et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 21 2008 3552 3559
4. T.S. Mok, Y.L. Wu, S. Thongprasert, and et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 10 2009 947 957
5. M. Fukuoka, Y.L. Wu, S. Thongprasert, and et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 21 2011 2866 2874
6. S.P. D'Angelo, Y.Y. Janjigian, N. Ahye, and et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib J Thorac Oncol 7 12 2012 1815 1822
7. N. Li, W. Ou, X. Ye, and et al. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study Ann Surg Oncol 21 6 2014 2091 2096
8. K. Kelly, N.K. Altorki, W.E. Eberhardt, and et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): a randomized, double-blind, phase III trial J Clin Oncol 33 34 2015 4007 4014
9. G.D. Goss, C. O'Callaghan, I. Lorimer, and et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study J Clin Oncol 31 27 2013 3320 3326
10. J.F. Tierney, L.A. Stewart, D. Ghersi, and et al. Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 2007 16
11. M.K. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 24 1998 2815 2834
12. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group Lancet 339 8784 1992 1 15
13. N. Mantel, and W. Haenszel Statistical aspects of the analysis of data from retrospective studies of disease Journal of the National Cancer Institute 22 4 1959 719 748
14. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 3 1986 177 188
15. D.G. Altman, and J.M. Bland Interaction revisited: the difference between two estimates BMJ 326 7382 2003 219
16. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 7109 1997 629 634
17. N.A. Pennell, J.W. Neal, J.E. Chaft, and et al. SELECT: a multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC J Clin Oncol 32 15 2014
18. C. Lv, C. An, Q. Feng, and et al. A retrospective study of stage I to IIIa lung adenocarcinoma after resection: what is the optimal adjuvant modality for patients with an EGFR mutation? Clin Lung Cancer 16 6 2015 e173 e181
19. C.L. Corless, K.V. Ballman, C.R. Antonescu, and et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial J Clin Oncol 32 15 2014 1563 1570
20. R.P. Dematteo, K.V. Ballman, C.R. Antonescu, and et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 9669 2009 1097 1104
21. C.S. Baik, M.C. Chamberlain, and L.Q. Chow Targeted therapy for brain metastases in EGFR-mutated and ALK-rearranged non-small-cell lung cancer J Thorac Oncol 10 9 2015 1268 1278
22. Y. Togashi, K. Masago, M. Fukudo, and et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer J Thorac Oncol 5 7 2010 950 955
23. A. Broniscer, J.C. Panetta, M. O'Shaughnessy, and et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 Clin Cancer Res 13 5 2007 1511 1515
24. H. Joensuu, M. Eriksson, K. Sundby Hall, and et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial JAMA 307 12 2012 1265 1272
25. J. Zhang, J. Fujimoto, D.C. Wedge, and et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing Science 346 6206 2014 256 259
26. Q. Huang, X. Su, A.E. Bella, and et al. Clinicopathological features and outcome of gastric metastases from primary lung cancer: a case report and systematic review Oncol Lett 9 3 2015 1373 1379
27. E.C. de Bruin, N. McGranahan, R. Mitter, and et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution Science 346 6206 2014 251 256
28. E.A. Perez, E.H. Romond, V.J. Suman, and et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 J Clin Oncol 32 33 2014 3744 3752
29. Cheng Y, Murakami H, Yang P, et al. Randomized trial of gefitinib with and without pemetrexed as first-line therapy in east-asian patients with advanced NS NSCLC with EGFR mutations. World Conference on Lung Cancer, September 6-9, 2015; Denver, CO. WCLC Meeting Abstracts; 2015.